Crawford S W, Pepe M, Lin D, Benedetti F, Deeg H J
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
Am J Respir Crit Care Med. 1995 Aug;152(2):690-5. doi: 10.1164/ajrccm.152.2.7633727.
To determine whether pulmonary function test (PFT) results after marrow transplantation were predictive of nonrelapse mortality, a review was made of prospective, nonrandomized PFT results for association with nonrelapse mortality by log-rank test and Cox proportional hazards modeling. The setting was a tertiary referral center. The patients were all marrow recipients who performed PFT between Days 60 and 120 after marrow transplantation between July 1, 1983 and December 31, 1990 (n = 906). At 3 mo after transplantation, the mean values for total lung capacity (TLC) and diffusing capacity decreased, and restrictive ventilatory defects (TLC < 80% of predicted) were noted in 34% of the cohort. Airflow rates (FEV1/FVC) were unchanged. A restrictive lung defect at 3 mo after transplant or a significant decline (> or = 15%) in TLC from baseline despite remaining within the normal range was associated with a twofold increased risk of nonrelapse mortality. Neither airflow obstruction nor impairment in diffusing capacity was associated with an increased risk. Abnormalities of the TLC at 3 mo after transplant were associated with death with respiratory failure, but not with an increased risk of chronic graft-versus-host disease (GVHD). There is an increase in the nonrelapse mortality rate associated with either the presence of a restrictive defect 3 mo after marrow transplantation or a significant decline in lung volume compared with baseline. This effect is most pronounced more than 1 yr after marrow transplant and appears to be a result of an increase in the rate of death with respiratory failure, not chronic GVHD.(ABSTRACT TRUNCATED AT 250 WORDS)
为了确定骨髓移植后的肺功能测试(PFT)结果是否可预测非复发死亡率,通过对数秩检验和Cox比例风险模型,对前瞻性、非随机的PFT结果与非复发死亡率的相关性进行了回顾性分析。研究地点为一家三级转诊中心。患者均为1983年7月1日至1990年12月31日期间接受骨髓移植,且在移植后60至120天内进行了PFT的骨髓接受者(n = 906)。移植后3个月,总肺容量(TLC)和弥散容量的平均值下降,34%的队列出现限制性通气功能障碍(TLC < 预测值的80%)。气流速率(FEV1/FVC)未改变。移植后3个月出现限制性肺功能障碍,或TLC较基线虽仍在正常范围内但显著下降(≥15%),与非复发死亡率增加两倍相关。气流阻塞和弥散功能受损均与风险增加无关。移植后3个月TLC异常与呼吸衰竭死亡相关,但与慢性移植物抗宿主病(GVHD)风险增加无关。与骨髓移植后3个月存在限制性缺陷或肺容量较基线显著下降相关的非复发死亡率增加。这种影响在骨髓移植后1年以上最为明显,似乎是呼吸衰竭死亡率增加的结果,而非慢性GVHD。(摘要截短于250字)